• Home  /
  • Research & Analysis   /
  • Two Hot Stocks on the Run: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), Novartis AG (NYSE:NVS)

Two Hot Stocks on the Run: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), Novartis AG (NYSE:NVS)

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)

The shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) started off the last trading session with the price of $34.64 while closing the day with the price of $33.41. The shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Fell -4.08% with the Loss of -1.23 points.

The shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) traded with the day volume of 1.48 Million shares whereas its average trading volume is 1.3 Million.

While analyzing the past performance of the stock we can see that the shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Loss -12.15% in the last week while Falling -30.34% in the last month. Past quarter performance shows the red light with -29.74%. The semi-annual and annual performance shows -39.2% and -15.29% respectively.

Some critical values of the shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to be discussed here are: the beta which shows the value at 1.33 while Average True Range of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) demonstrate the value at 2.59. The weekly and monthly volatility of the shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) are indicated at 4.53% and 6.21%. Also to discuss here is the Relative Strength Index or RSI which is depicted at 31.35.

While studying the financial position of the shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), we can see that the Market capitalization of the company is at 2.27 Billion. The shares outstanding for the company is 67.8 Million and the shares float stands at 65 Million. The income of the company stand at -286100000 while the sales stand at 22.5 Million.

Here are some critical ratios for a financial perspective: Earnings Per Share or EPS of the company stand at -4.77, Price to Earnings or P/E is at 0, Price to Sales P/S show the value of 100.68, the Return on Asset ROA stood at -0.619 and the Return on Equity ROE depicted at -1.095 while Return on Investment ROI is at -0.604.


Novartis AG (NYSE:NVS)

Novartis AG (NYSE:NVS) started its previous trading session at $81.95 and closed at $81.23 showing a Fell of -1.01 Percent.

The Company traded with an average Volume of 1.56 Million whereas, its Day Volume stood at 1.47 Million.

Looking at the performance of the stock, Novartis AG (NYSE:NVS) Loss -2.03% in the last week in its shares price and -6.29% in the last month. Quarterly performance shows a red of -3.84 Percent while Semi-Annual and Annual performances shows a -5.08 and 7.52 percent respectively.

Beta for Novartis AG (NYSE:NVS) stands at 0.78 while the ATR (average true range) is at 1.18. The Stock’s Weekly and Monthly Volatility is 1.12% and 1.18% respectively showing a RSI value of 39.49.

While studying the financial position of the shares of Novartis AG (NYSE:NVS), we can see that the Market capitalization of the company is at 213.96 Billion. The shares outstanding for the company is 2.63 Billion and the shares float stands at 2.57 Billion.

The Company generated an income of 7.76 Billion and the sales of 50.14 Billion in the Trailing Twelve Months period.

While analyzing the stock from technical aspects, Diluted Earnings per share stands at $3.28 a share. P/E (price to earnings) and P/S (price to sales) values are 24.79 and 4.27 respectively.

The Return on Assets stands at 0.058, ROE shows a value of 0.108 and ROI for Novartis AG (NYSE:NVS) is 0.072 as of Trailing Twelve Months period.

The following two tabs change content below.

Eldred Matthew

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a comment